|
Management and Treatment of Hepatitis C Viral Infection: Table 9
 Table 9. General Guidelines for Ribavirin Dose Reduction or Discontinuation| PARAMETER | RECOMMENDATION |
|---|
| In stable underlying cardiac disease, reduce ribavirin by 200 mg/day for ≥2 g/dL drop in Hb over a four-wk period. If the Hb level is <12 g/dL after four wk of dose reduction, discontinue ribavirin until resolution and reevaluation. | | Hemoglobin (Hb) | | <11.0 but >10 g/dL | No change in ribavirin dose if patient has minimal symptoms | | | In a symptomatic patient, consider ribavirin dose reduction by 200 mg/day and/or starting an erythropoietic growth factor | | <10.0 but >8.5 g/dL | Decrease ribavirin by 200 mg/day and/or consider starting an erythropoietic growth factor | | | Recheck Hb levels at least every 2 wk or more frequently if indicated | | <8.5 g/dL | Discontinue until resolution | |
